SeaStar Medical Holding Corporation Common Stock Earnings Recaps

ICU Health Care 2 recaps

Next earnings: August 12, 2026 (estimated) · full calendar

Q2 2026 May 17, 2026

SeaStar Medical shares dropped 13.2% as investors reacted negatively to cautious guidance and ongoing clinical trial enrollment delays that cloud near-term revenue growth visibility.

Key takeaways

First quarter QUELIMMUNE net revenue increased 69% year-over-year to $495,000, driven by adoption at 7 new hospitals, on track for approximately $2 million full-year net revenue.
Patient enrollment in the pivotal NEUTRALIZE-AKI adult trial stands at 198 of 339 planned patients, with additional clinical sites added to target end-of-year enrollment completion.
Management emphasized continued FDA discussions on modular PMA submissions and rapid approval pathways, but progress timelines remain uncertain.
Despite growing pediatric market presence and recognition in nephrology circles, no updated revenue guidance or acceleration signals were provided.
The market’s negative response reflects investor concern over the pace of transitioning to the larger adult AKI opportunity and visibility on margin or profitability improvements.

Q1 2026 May 15, 2026

SeaStar Medical’s stock dropped 13.2% after the quarter, driven primarily by cautious commentary on the pace of enrollment in the NEUTRALIZE-AKI pivotal trial and the still small commercial scale of QUELIMMUNE revenue, which constrains near-term growth visibility.

Key takeaways

QUELIMMUNE revenue increased 69% year-over-year to $495,000, supported by the addition of 7 new hospital customers in Q1.
The company maintains a target of 15 new hospital adoptions for the full year, reflecting modest but steady customer growth.
Enrollment for the adult AKI pivotal trial stands at 198 of 339 planned patients, with efforts underway to expand clinical sites to complete enrollment by end of 2026.
Management highlighted ongoing discussions with the FDA on modular PMA submission and potential rapid approval pathways, but no new regulatory milestones were announced this quarter.
Despite commercial and clinical progress, the relatively early-stage adoption and cautious outlook on trial enrollment tempo likely contributed to investor disappointment.